President
HTD Biosystems Inc.
Livermore, California
Dr. Rajiv Nayar is the Founder and President of HTD Biosystems. Previously, he was at Bayer where he founded the formulation and drug delivery group. His group was responsible for formulation and drug delivery activities across Bayer's global network, focusing on biopharmaceuticals. His contributions were recognized through three consecutive Presidential Achievement Awards for his role in implementing Continuous Improvement Processes in pharmaceutical development.
Dr. Nayar holds 28 patents and has contributed to over 70 publications. He is notably credited with inventing Bayer's albumin-free Factor VIII formulation, Kogenate® FS, marking a significant advancement in hemophilia treatment. Before his tenure at Bayer, Dr. Nayar was involved in pioneering work at the Canadian Liposome Company on developing liposomal drug delivery systems in oncology. His contributions led to the development of liposomal doxorubicin (Caelyx®, Myocet®) and vincristine (Marquibo®).
At HTD Biosystems, Dr. Nayar has led the development of numerous drug products from inception to clinical trials, specializing in lyophilization, vaccine development, and innovative drug delivery systems, particularly focusing on liposomes and lipid nanoparticles (LNPs). Dr. Nayar received his Ph.D. in Biochemistry from the University of British Columbia and was a postdoctoral fellowship at the M.D. Anderson Tumor Institute as an Medical Research Council fellow.
Disclosure information not submitted.
Hot Topic: Phase-Appropriate Strategies for Gene and Cell Therapy Regulatory Compliance
Tuesday, October 22, 2024
9:00 AM – 10:00 AM MT